Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Alphabet Inc Class A — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Alphabet Inc Class A trades at $345.56 (market cap $4.20T). The key difference: Alphabet Inc Class A is far larger — about 445.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Alphabet Inc Class A pays a 0.26% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | GOOGL | |
|---|---|---|
Market Cap | $9.43B | $4.20T |
Sector | Health | Media |
52-Week High | $362.08 | $402.62 |
52-Week Low | $241.71 | $199.32 |
Enterprise Value | $9.18B | $4.09T |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $362.08, up 2.13% daily, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, Q2 2026 earnings beat estimates with EPS of $2.62 versus $1.75 expected, and revenue remains stable around $2.6 billion. Net income turned positive in 2025 after prior losses, with a current net margin of 29.41%. Analyst consensus is Buy with a $350 price target, and institutional holdings increased, as noted by Amundi's 1,763.4% stake growth per SEC filing on August 5, 2026.
Outlook is cautiously optimistic with solid earnings recovery and institutional support, but risks include high P/E of 43.39, potential overvaluation, and reliance on academic research markets. Investors should weigh strong profitability against valuation concerns and monitor upcoming Q3 earnings for sustained growth.
Alphabet (GOOGL) trades at $343.8, down 3.84% over 24 hours, with a bearish technical signal but strong fundamentals. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight robust profit growth, with net income reaching $132.17 billion in 2025. The stock faces near-term pressure from technical indicators but benefits from AI-driven revenue expansion and a consensus analyst price target of $426.28, suggesting significant upside potential.
The outlook remains positive due to solid earnings performance and AI investments, though risks include antitrust scrutiny and market volatility. With 85% of analysts rating it a buy, GOOGL offers long-term growth opportunities, but investors should monitor competitive and regulatory challenges that could impact valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
